Anteris Technologies shares surge 15.99% premarket after 30-day DurAVR THV trial shows 97% freedom from prosthesis-patient mismatch in small annuli patients.

Anteris Technologies (NASDAQ: AVR) surged 16.00% in premarket trading following the release of 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in 100 patients with small aortic annuli. The data, presented at PCR London Valves and published in EuroIntervention, highlighted favorable hemodynamics, including a mean pressure gradient of 8.2 mmHg and an effective orifice area of 2.2 cm², alongside no valve-related mortality or paravalvular leaks. Notably, 97% of patients avoided moderate/severe prosthesis-patient mismatch, a critical predictor of valve failure, outperforming existing devices. The 100% technical success rate in the last 50 implants and alignment with earlier trial results bolstered confidence in the DurAVR® THV’s potential for commercialization. These outcomes reinforced the company’s position in structural heart disease innovation and signaled progress toward the global PARADIGM Trial, driving the premarket rally.